No data are present in the literature regarding chemokine (CXC motif) ligand (CXCL)9 and CXCLll circulating levels in cryoglobulinemia associated with hepatitis C (MC+HCV), in presence/absence of autoimmune thyroiditis (AT). Serum CXCL9 and CXCLll have been measured in 38 MC+HCV patients without AT (MCo), 38 MC+HCV patients with AT (MC+AT), and in matched controls without (control 1) or with thyroiditis (control 2). Serum CXCL9 and CXCLll were significantly higher: in control 2 than control 1 (p<O.05); in MCo than control 1 and control 2 (p<O.OOI, for both); in MC+AT than control 1 and control 2 (p<O.OOOI, for both), and than MCo (p=O.OI, for both). Our study demonstrates markedly high serum levels of CXCL9 and CXCLll in patients with MC+HCV compared to healthy controls; in MC+HCV patients increased CXCL9 and CXCLlllevels were significantly associated with the presence of AT. Moreover, a strong relation between circulating CXCL9 and CXCLll in MC+HCV has been shown.
in this phase (3, 4) . Furthermore, it has been shown CXCLl°is higher in MC with autoimmune thyroiditis (AT), with respect to those without (5, 6) , accordingly with other studies in patients with autoimmune disorders without HCV infection (7, 8) .
No study has evaluated CXCLlI, together with CXCL9, circulating levels in patients with cryoglobulinemia associated with hepatitis C (MC+HCV), with or without AT. Furthermore, a few studies evaluated CXCL9 and CXCL II in thyroid autoimmunity. In fact, it has been recently shown that CXCL9 and CXCL II circulating levels are higher in patients with AT (9) , and that the secretion of CXCL9 and CXCL II in primary cultures of human thyrocytes can be stimulated by IFN-y and tumor necrosis factor-a (10, 11) . These data suggest that CXCL9 and CXCL 11 chemokines are involved in the Th I immune response that is pathogenetically associated with the initial phase of AT.
The aim of the present study therefore was to measure serum CXCL9 and CXCLlI levels in patients with MC+HCV, with or without AT, and to relate the findings to the clinical phenotype.
MATERIALS AND METHODS

Patients with MC+HCV
Thirty-eight MC+HCY patients without autoimmune thyroiditis (MCo), and 38 patients with MC+HCY and autoimmune thyroiditis (MC+AT), consecutively referred to the Rheumatology Unit ofthe University of Modena and Reggio Emilia were recruited into the study (enrolment start date, January 1995). The diagnosis ofMC was based on the presence of serum mixed (IgG-lgM) cryoglobulins and the classical clinical triad -purpura, weakness, arthralgias -and on the exclusion of other well-known systemic disorders, such as immuno-rheumatic, neoplastic, and infectious diseases (12, 13) . HCY infection was systematically evaluated in all patients, and HCY negative were excluded. Only patients with MC+HCY, without liver cirrhosis (by histology, laboratory evidence of liver failure and/or ultrasound-proven portal hypertension) (14) and without hepatocellular carcinoma, in whom a thyroid screening [history, physical examination, thyroidstimulating hormone (TSH), free triiodo-thyronine (FT j ) , free-thyroxine (FT 4 ) , anti-thyroglobulin (AbTg) and antithyroid peroxidase (AbTPO) antibodies measurements and ultrasonography] excluded (MCo), or revealed (MC+AT) the presence of associated thyroid autoimmune disorders, were included in these groups.
Fifty-one out of 76 (67%) MC+HCY patients underwent liver biopsy for diagnostic purposes; the mean activity index (grade) was 5.3±1.1, and the stage was 2.2±0.6; mean alanine aminotransferase (ALT) serum levels were 53±44 (reference values, 5-36 lUlL); high levels of Rheumatoid Factor were present in 98% of MC+HCY patients.
The main demographic and clinico-serological features of MCo patients are reported in Table 1 . Among them, 20 had been previously treated with IFN-a for an average of7.2 months (range 1-14), at a mean dosage of 9 MU/week (range 3-9); the time elapsed from the last course of IFN-a treatment ranged from 5 to 92 months (mean 44). No statistically significant difference was observed in the main demographic and clinico-serological features of MC patients treated (MC/IFN+) or untreated
At the time of the study, 21 MCo patients were taking low doses of corticosteroids, 8 had previously been on corticosteroids and 9 had never been treated with corticosteroids. No MC patient had had plasma exchange treatment in the last year before the study. The presence of Raynaud's phenomenon, Sjogren's syndrome, skin ulcers, peripheral neuropathy, and renal and liver involvement in MCo patients was evaluated as previously described (12) . Routine blood chemistry was carried out by standard methods.
The main demographic and clinico-serological features of MC+AT patients are reported in Table 1 . Among them, 20 had been previously treated with IFN-a for an average of 5.9 months (range 1-12), at a mean dosage of 12 MUI week (range 3-10); the time elapsed from the last course of IFN-a treatment ranged from 3 to 65 months (mean 37). No statistically significant difference was observed in the main demographic and clinico-serological features of MC patients treated (MC/IFN+) or untreated (MC/IFN-) with IFN-a.
At the time of the study, 21 MC+AT patients were taking low doses ofcorticosteroids, 6 had previously been on corticosteroids and II had never been treated with corticosteroids. No MC patient had had plasma exchange treatment in the last year before the study. The presence of Raynaud's phenomenon, Sjogren's syndrome, skin ulcers, peripheral neuropathy, and renal and liver involvement in MC+AT patients was evaluated as previously described (12) . Routine blood chemistry was carried out by standard methods.
Controls
Two control groups were included, extracted from a random sample of the general population from the same geographic area (15) .
The first control group (control 1) consisted of 38 subjects, matched by gender and age [that is a well known confounding factor (16) ] with MCo patients, without HCY infection or other liver disorders, in whom a complete thyroid work-up (history, physical examination, TSH, FT 3 , FT 4 , AbTg, AbTPO, and ultrasonography) was available, and excluded the presence of thyroid or autoimmune disorders, or any kind of immunomodulant therapy.
The second control group (control 2) consisted of 38 subjects, matched by gender and age [that is a well known confounding factor (16)] with MC+AT patients, without HCY infection or other liver disorders, in whom a complete thyroid work-up (history, physical examination, TSH, FT 3 , FT 4 , AbTg, AbTPO, and ultrasonography) was available, and demonstrated the presence of thyroid autoimmune disorders, but excluded the presence of other autoimmune disorders and any kind of immunomodulant therapy.
In all patients and controls, a blood sample was collected in the morning, after overnight fasting, and serum was kept frozen until CXCL9 and CXCL 11 measurement.
All study subjects gave their informed consent to the study, which was approved by the local Ethics Committee.
Immunological studies
Cryocrit was measured as the percentage of packed cryoglobulins after cold centrifugation of the serum; cryoglobulin composition was determined by including the presence in cryoprecipitates of monoclonal or polyclonal IgM-rheumatoid factor, (i.e. MC type II or MC type III); haemolytic complement activity (CH50) and C3-C4 fractions were measured as previously described (12) ; anti-nuclear (ANA), anti-smooth muscle (ASMA), and anti-mitochondrial (AMA) autoantibodies were detected by current techniques (12) . Sera with a titre> 1:40 were considered positive. Anti-extractable nuclear antigen (ENA) antibodies, including anti-Scl70, anti-Sm, -RNP, -SSAISSB, -PCNA, -SL and -101 specificities, were detected by counter-immunoelectrophoresis as previously reported (14) .
Virological studies
Anti-HCY antibodies and HCY RNA were determined on serum clotted and centrifuged at 37°C and stored at -70°C. Antibodies against HCY (anti-HCY) were detected by an enzyme-linked immunoassay (Chiron ELISA HCY, Second Generation; Emeryville CA, USA). A recombinant-based immunoblot assay (Chiron RIBA HCV, Second Generation Assay; Emeryville CA, USA) was used to investigate the specificity of anti-HCY seropositivity. The presence of HCY RNA in the serum was investigated by a polymerase chain reaction (PCR) technique as previously described (17) . Amplification of HCY cDNA was performed using a 'nested' PCR, with primers located in the 5' non-coding region (17) . The analysis of amplification products was performed by both ethidium bromide staining and hybridisation with a radiolabelled oligonucleotide probe internal to the amplified sequence.
Ultrasonography of the neck and fine-needle aspiration (FNA)
Neck ultrasonography was performed by the same operator, who was unaware of the results of thyroid hormones, autoantibodies and CXCLl 0 measurements, using a probe (Esaote, Florence, Italy; AU5 with a sectorial 7.5 MHz transducer). Thyroid volume was calculated using the ellipsoid formula, as described (7) . The presence of hypoechoic and dyshomogeneous echogenicity was arbitrarily rated at three levels (O=normal echogenicity; 1=slight hypoechoic and dyshomogeneous; 2=severely hypoechoic and dyshomogeneous) in order to evaluate structural abnormalities of thyroid tissue associated with thyroid autoimmunity (7) . The presence of thyroid nodules was recorded, and nodules with a diameter> 10 mm were submitted to ultrasonography-guided FNA, which was performed by the same operator, using a freehand method as already described (7) .
Thyroid bloodjiow (TBF)
TBF by color-flow doppler (CFD) was studied in all patients (7) . The CFD pattern was defined as: normal (or type 0), TBF limited to peripheral thyroid arteries; type I, TBF mildly increased; type II, TBF clearly increased; or type III, TBF markedly increased (7) . In AT patients TBF bore no relation to the thyroid status, and was type 0 in 58%, type I in 34%, type II in 8% of patients, while none had type III CFD pattern.
Laboratory evaluation
Thyroid function and thyroid autoantibodies were measured as previously described (7) . Circulating FT and FT were measured by commercial radioimmunoassay kits (AMERLEX-MAB FT 1FT Kit; Amersham Biosciences, Little Chalfont, UK). Seruk TSH (DiaSorin, Saluggia, Italy), AbTPO and AbTg (lCN Pharmaceuticals, Costa Mesa, CA, USA) were evaluated by immunoradiometric assay methods. For AbTg, AbTPO, positivity was set at >50, and> 10 IU/mL, respectively.
Serum CXCL9 andCXCLI1enzyme-linkedimmunosorbent assay
Serum CXCL9 and CXCLll levels were assayed by a quantitative sandwich immunoassay (R&D Systems, Minneapolis, MN, USA). Sensitivity ranged from 1.3-12.7 pg/mL with a mean minimum detectable dose of 3.4 pg/mL for CXCL9; the intra-and inter-assay coefficients of variation were 4.1% and 6.4%. The CXCL II sensitivity ranged from 0.4-3.7 pg/mL with a mean minimum detectable dose of 11.8 pg/mL; the intra-and inter-assay coefficients of variation were 4.2% and 6.7%.
Data analysis
Values are given as mean±standard deviation (SD) for normally distributed variables, otherwise as median and [interquartile range]. Mean group values were compared by using one-way analysis of variance (ANOVA) for normally distributed variables (age and body mass index), otherwise by the Mann-Whitney U or Kruskal-Wallis test. Proportions were compared by the X 2 test. Posthoc comparisons on normally distributed variables were carried out using the Bonferroni-Dunn test. Univariate and multivariate analysis were performed by simple or multiple linear regression analysis. Statistical power (ex post analysis) (stat-power) was calculated.
RESULTS
MCo and MC+AT patients were not significantly different in relation to the clinical phenotype of cryoglobulinemia (Table I) . The demographic and clinical thyroid features of patients and controls are reported in Table II . As expected, MC+AT patients, and controls with AT (control 2) showed significantly higher thyroid autoantibodies levels, as well as hypoechogenicity and hypervascularity of the thyroid gland, and subclinical hypothyroidism in comparison to control 1 and MCo.
Serum CXCL9 levels were significantly (Table  II) higher in control 2 thyroiditis, than in control I (p<0.01). MCo have serum CXCL9 levels significantly (p<0.000 1) (stat-power= 1) higher than control 1 without thyroiditis ( Fig. 1 ) and controls 2 with thyroiditis. MC+AT have serum CXCL9 levels significantly higher (p<0.000 1) (stat-power=l) than control 1 and 2 (Fig. 1 ), or MCo (p=0.01) (stat-power=0.8). Serum CXCL9 levels were not associated with any of the clinical features of cryoglobulinemia in patients MCo and MC+AT (data not shown).
Serum CXCLll levels were significantly (Table  II) higher in control 2 thyroiditis, than in control 1 (p=0.02). MCo have serum CXCLll levels significantly higher than control 1 and control 2 (p<0.001, for both) (stat-power=l) (Fig. 2) . MC+AT have serum CXCL 11 levels significantly higher than control 1 and 2 (p<0.0001, for both) (stat-power=l) (Fig. 2) , and than MCo (p=0.01) (stat-power=0.8). Serum CXCLII levels were not associated with any of the clinical fetaures of cryoglobulinemia in patients MCo and MC+AT (data not shown).
In order to better define the role of increased serum chemokines in AT, CXCL9 and CXCLll were studied in relation to clinical features of AT (age; gender; thyroid volume <6 mL; thyroid hypoechoic pattern, or hypervascularity; AbTg or AbTPO positivity; subclinical hypothyroidism) in MC+AT patients and control 2, without any significant result. By defining a high CXCL9 level as a value of at least 2 SD above the mean value of the control group (>125 pg/mL), 4% of control 1,29% of control 2, 87% ofMCo and 98% ofMC+AT, had high CXCL9 (p<0.0001; x2test).
By defining a high CXCL 11 level as a value of at least 2 SD above the mean value of the control group (>110 pg/mL), 4% of control 1, 28% of control 2, 88% ofMCo and 98% ofMC+AT, had high CXCLll (p<0.000 1; X 2 test).
No significant association was observed in relation to the presence or absence of active or previous treatments, or in relation to the duration of MC, and CXCL9 or CXCLll circulating levels.
In a simple regression analysis CXCL9 and CXCL 11 serum levels were significantly related to each other (r=0.547, p<O.OOOl) in MC+HCY patients.
DISCUSSION
Our study first demonstrates high serum levels of CXCL9 and CXCL 11 chemokine in patients with MC, in particular in the presence of AT. Moreover, to the best of our knowledge, we have first shown strong association between CXCL9 and CXCLll circulating levels in these patients, strongly supporting the role ofa Thl immune response in the pathogenesis ofMC+HCV.
Our results agree with those of other studies in patients with HCY infection without cryoglobulinemia.
Increased circulating levels of CXCL9 (18) (19) (20) (21) (22) and CXCLll (18, 20, 23) , were observed in some studies, while other studies were no able to show any significant difference with controls (24). Bieche et al. studied the expression of 240 genes in patients with HCY chronic infection (25) . They showed mRNA level up-regulation of IFN-y-inducible genes (CXCL9, CXCLlO, CXCLlI). These results suggest that CXCL9 and CXCLlI, potent chemo attractants for activated T cells, are produced by hepatocytes in the HCY-infected liver and play an important role in the pathogenesis ofMC.
In our MC+HCY patients CXCL9 and CXCLll serum levels were significantly higher than in controls. The possible contribution of chronic hepatitis C to high CXCL9 and CXCLlI serum levels in MC+HCY patients cannot be excluded. Furthermore, the increase of CXCL9 and CXCL II is in agreement with recent evidences, that have shown that CXCLl°plays an important role in cryoglobulinemia. In fact, circulating CXCLl 0 is high in particular in cryoglobulinaemic patients with active vasculitis, suggesting a prevalence of the Thl immune response in this phase (3, 4) .
In our study we did not find any relation among serum CXCL9 or CXCLlI levels and the duration of MC+HCV, probably because the disease is characterized by a relapsing clinical course whose *** most common expression are vasculitic symptoms (26) . Clinico-pathological alterations of MC+HCY may recognize at least two synergical pathogenetic mechanisms triggered by HCY. Firstly, B-cell proliferation leads to immune-complexes production (cryoglobulins) (26) , that are responsible for immune-complex-mediated vasculitis (13, 26) , while high serum CXCL9 and CXCLlI levels secondary to both HCY-related vascular and hepatic cell injury may amplify the inflammatory process through Thlmediated immune response.
Change of serum chemokine levels in the course of other autoimmune disorders has been demonstrated. Recent experimental evidence has demonstrated that CXC chemokines and particularly CXCLl 0 play an important physiopathological role in the initial phases of autoimmune thyroid disorders (7, 27) . Furthermore, we have recently shown that increased serum CXCLl 0 levels in patients with Graves' disease (GD) are associated mainly with the active phase of GD, not related to hyperthyroidism itself, but mainly to autoimmune response (8) .
Interestingly, this study first shows serum CXCL9 and CXCLlI were higher in MC+AT patients with respect to MCo, such as in AT patients with respect to controls without AT, in agreement with the abovementioned studies. Furthermore, it has been recently shown that CXCL9 and CXCL 11 circulating levels in AT patients were associated with high serum TSH concentrations, suggesting that raised CXCL9 and CXCLlI chemokines are not only associated with the autoimmune process itself, but may be a marker of a thyroiditic process eventually leading to the destruction of thyroid follicular cells (9, 28).
We were not able to find any relationship among CXCL9 or CXCLlllevels and hypothyroidism in the present study,probably because ofthe limited number of patients studied. Longitudinal studies evaluating serum CXCL9 and CXCLlllevels in large MC+HCY patient series will be necessary to evaluate whether serum CXCL9 or CXCL11 measurement could represent an easily detectable prognostic marker for clinical management of MC+HCY patients, with or without thyroiditis.
Recently, it was shown that a low baseline CXCL 10 level was significantly associated with low baseline viral load, rapid viral response, and sustained viral response in HCY+ patients treated with IFN-a 1000 *** (29) (30) (31) . In another study, levels of CXCLl 0 and CXCL9 decreased following successful antiviral therapy in HCY+ patients, while CXCLll did not decline (18) .
Since IFN-a is a well known effective therapy for MC+HCY (26) , pretreatment evaluation of serum of CXCL9 or CXCLlI levels might suggest the virological response to IFN also in MC+HCY patients.
Interestingly, to the best of our knowledge, this is the first demonstration of a strong relation between circulating CXCL9 and CXCL 11, in a human pathology, such as MC+HCY in presence or absence ofAT. This finding strongly supports the role ofa Th 1 immune response in the pathogenesis of MC+HCV.
In conclusion, our study demonstrates markedly high serum levels of CXCL9 and CXCLll in patients with MC+HCY compared to healthy controls; in MC+HCY patients increased CXCL9 and CXCLll levels were significantly associated with the presence ofAT. Moreover, a strong relation between circulating CXCL9 and CXCL 11, in MC+HCY has been shown. Future studies in larger cohort of patient will be needed to evaluate the relevance of serum CXCL9 and CXCLll in the therapeutic approach to these patients.
